**Low-Cost Generic Semaglutide Floods Markets Amid Patent Battles**
**Meta Description:** Indian manufacturers are racing to export generic semaglutide, but Bangladesh has already established a foothold in the market with low-cost alternatives.
**URL Slug:** low-cost-generic-semaglutide-market
**Headline:** Indian Drugmakers Race to Export Generic Semaglutide as Bangladesh Leads the Way
In a significant development in the pharmaceutical industry, Indian manufacturers are gearing up to export generic versions of semaglutide, a popular weight-loss drug, to countries without patent protections. This move comes as the Delhi High Court recently permitted Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries to produce and export generic semaglutide to non-patent-holding nations. However, both companies are restricted from selling the drug domestically until the patent held by innovator Novo Nordisk expires in March 2026.
While Indian firms are eager to capitalize on the lucrative market for semaglutide, they are not the first to venture into non-patented territories. Bangladesh has already made significant inroads, leveraging its status as a ‘least-developed country’ under World Trade Organization (WTO) agreements, which allows it to manufacture patented drugs until 2030. This exemption has enabled Bangladeshi manufacturers to supply low-cost generic semaglutide to various markets for over two years, positioning them ahead of Indian competitors.
Semaglutide, primarily used for treating Type 2 diabetes and aiding chronic weight management, has seen a surge in demand. However, experts caution that entering regulated markets will require navigating patent expirations and obtaining necessary approvals. Brand recognition will also play a crucial role in the competitive landscape, particularly as companies from Bangladesh continue to dominate due to less stringent regulations.
Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), noted that competition in the rest-of-the-world (RoW) markets is intense, especially from countries like Bangladesh, where regulatory oversight is minimal.
As Indian drugmakers prepare to launch their versions of semaglutide, they face a race against time. Some companies have already initiated patent challenges against Novo Nordisk, with Dr. Reddy’s being the first to contest the patent’s validity in May. The Delhi High Court recently ruled in favor of Dr. Reddy’s, allowing it to continue exporting to non-patent countries, while Sun Pharma received similar permissions shortly thereafter.
Both companies have commenced the manufacturing of generic semaglutide, setting the stage for a competitive market landscape as they await the expiration of patents in India.
**FAQ Section**
**Q: What is semaglutide used for?**
A: Semaglutide is primarily used to treat Type 2 diabetes and assist with chronic weight management.
